Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionStandard Life Aberdeen plc
Latest Disclosed Ownership1,854,446 shares
Latest Disclosed Value $ 35,605,363
Standard Life Aberdeen plc reports 8.78% decrease in ownership of DNLI / Denali Therapeutics Inc.

On April 29, 2026 - Standard Life Aberdeen plc filed a 13F-HR form disclosing ownership of 1,854,446 shares of Denali Therapeutics Inc. (US:DNLI) valued at $35,605,363 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 16, 2026 disclosing 2,032,967 shares of Denali Therapeutics Inc.. This represents a change in shares of -8.78% during the quarter. The current value of the position is $36,198,786 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-29 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 1,854,446 -178,521 -8.78 35,605 6.08 0.0312
2026-01-16 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 2,032,967 919,381 82.56 33,564 107.58 0.0520
2025-11-07 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 1,113,586 210,835 23.35 16,169 28.03 0.0256
2025-07-24 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 902,751 142,936 18.81 12,629 22.27 0.0215
2025-05-13 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 759,815 357,533 88.88 10,330 25.99 0.0201
2025-01-24 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 402,282 38,603 10.61 8,199 -22.61 0.0154
2024-10-25 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 363,679 -209,356 -36.53 10,594 -20.38 0.0194
2024-08-09 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 573,035 57,016 11.05 13,306 25.66 0.0255
2024-05-09 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 516,019 191,190 58.86 10,589 51.91 0.0208
2024-01-31 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 324,829 324,829 6,971 0.0151
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.